SGLT2 inhibitors in cardiac amyloidosis: mechanistic insights and clinical perspectives-a narrative review
Abstract
Background: Cardiac amyloidosis (CA) is an infiltrative cardiomyopathy characterized by progressive extracellular amyloid deposition, leading to restrictive heart failure (HF) and high morbidity. Disease-modifying therapies remain limited, particularly in patients with advanced HF. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, originally developed for diabetes management, have shown consistent cardiovascular and renal benefits in large randomized trials of non-amyloid HF populations. Their potential mechanistic and clinical relevance in CA has recently gained attention, yet evidence remains largely observational.
Main text: This narrative review, based on literature identified through PubMed, Embase, and Cochrane Library searches up to October 2025, summarizes emerging mechanistic and clinical insights on the potential role of SGLT2 inhibitors in CA. Preclinical and translational data suggest that SGLT2 inhibition may favorably influence key pathophysiologic pathways, including hemodynamic, metabolic, inflammatory, fibrotic, renal, and endothelial mechanisms. Observational and registry studies have reported associations with improved survival, symptoms, stable renal function, and favorable biomarker trajectories, although these findings derive from retrospective analyses with inherent limitations. No randomized controlled trials (RCTs) have specifically evaluated SGLT2 inhibitors in CA, and the risk of immortal time bias and residual confounding limits causal…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.